Hengrui Yuanzheng Bio

Hengrui Yuanzheng is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of solid tumors. As a specialized cell therapy entity associated with Jiangsu Hengrui Pharmaceuticals, the company leverages its proprietary MASCT (Multi-Antigen Stimulated Cell Therapy) and TCR-T platforms to target a wide range of cancers. Its lead programs include personalized cellular vaccines and engineered T-cell therapies designed to overcome the immunosuppressive environment of solid tumors. The company is headquartered in Shanghai and maintains a robust pipeline of next-generation immunotherapies. Hengrui Yuanzheng aims to provide effective treatment options for patients with advanced malignancies through its advanced cell engineering technologies.